Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Transcriptomic features of FAP+ cells across molecular subtypes of breast cancer

Kalinchuk AYu, Patskan IA, Stadelman MM, Grigoryeva ES, Tashireva LA
About authors

Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Correspondence should be addressed: Evgeniya S. Grigoryeva
Koperativny Lane, str. 7, Tomsk, 634009, Russia; moc.liamg@se.aveyrogirg

About paper

Funding: this work was supported by the Russian Science Foundation (grant No. 25-65-00021).

Author contribution: Kalinchuk AYu — writing and formatting; Patskan IA — bioinformatic analysis; Shtadelman MM — data collection and analysis; Grigoryeva ES — interpretation of results; Tashireva LA — interpretation of results, concept development. All authors participated in the final editing of the article.

Compliance with ethical standards: The study was approved by the Ethics Committee of the Tomsk National Research Medical Center of Oncology (Protocol No. 3 dated August 25, 2020). The work was conducted in accordance with the principles of the Helsinki Declaration (1964) and its amendments (1975 and 1983). All patients provided written informed consent to participate in the study.

Received: 2025-09-10 Accepted: 2025-10-08 Published online: 2025-10-16
|
Fig. 1. A. Clusters of FAP+ cells in luminal (brown) and triple-negative (yellow) breast cancer patients obtained by combining data in Space Ranger v1.3 software. B. Tissue section of a luminal breast tumor with identified FAP+ spots. C. Tissue section of a triple-negative breast tumor with identified FAP+ spots
Fig. 2. Significant signaling pathways activated in FAP+ regions of luminal (A) and triple-negative (B) breast tumors
Fig. 3. Fibroblast-specific genes in FAP+ regions of luminal and triple-negative breast tumors
Fig. 4. Genes associated with radioresistance in FAP+ regions of luminal and triple-negative breast tumors